mTOR Pathway and mTOR Inhibitors in Cancer Therapy
mTOR Pathway and mTOR Inhibitors in Cancer Therapy provides an up-to-date survey of the rapidly advancing field of cancer therapy. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the
- PDF / 4,725,346 Bytes
- 306 Pages / 439.37 x 666.142 pts Page_size
- 69 Downloads / 197 Views
Series Editor Beverly A. Teicher Genzyme Corporation, Framington, MA, USA
For further volumes: http://www.springer.com/series/7625
Vitaly A. Polunovsky · Peter J. Houghton Editors
mTOR Pathway and mTOR Inhibitors in Cancer Therapy
Editors Vitaly A. Polunovsky Professor of Medicine Department of Family Medicine University of Minnesota Minneapolis, Minnesota 55455 USA [email protected]
Peter J. Houghton Director, Center for Childhood Cancer Elizabeth M. and Richard M. Ross Chair The Research Institute Nationwide Children’s Hospital 700 Children’s Drive Columbus, OH 43205 [email protected]
ISBN 978-1-60327-270-4 e-ISBN 978-1-60327-271-1 DOI 10.1007/978-1-60327-271-1 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2010930694 © Springer Science+Business Media, LLC 2010 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper Humana Press is part of Springer Science+Business Media (www.springer.com)
A theory is more impressive the greater the simplicity of its premises, the more different kinds of things it relates, and the more extended its area of applicability Albert Einstein
Preface
The main objective of this book is to provide an up-to-date survey of the rapidly advancing field of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment – targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. The target of rapamycin (TOR) was first identified in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/t
Data Loading...
